AGIOS PHARMACEUTICALS, INC.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|
| Revenue | $41.5M | $71.7M | $89.2M | $92.0M | $54.1M | $31.2M | $21.8M |
| Product Revenue | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Collaboration Revenue | $41.4M | $71.7M | $89.2M | $92.0M | $54.1M | $31.2M | — |
| Royalty Revenue | $132.0K | $0 | $0 | $0 | $0 | $0 | — |
| Cost of Revenue | $0 | $0 | — | — | — | — | — |
| Gross Profit | $41.5M | $71.7M | — | — | — | — | — |
| Gross Margin | 100.0% | 100.0% | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | $292.7M | $220.2M | $141.8M | $100.4M | $54.5M | $41.0M | $31.3M |
| SG&A Expense | $71.1M | $50.7M | $36.0M | $19.1M | $9.9M | $7.1M | $7.2M |
| Operating Income | $-320.8M | $-201.0M | $-118.7M | $-54.1M | $-38.9M | $-23.0M | $-16.6M |
| Operating Margin | -772.4% | -280.4% | -133.1% | -58.9% | -71.8% | -73.7% | -76.2% |
| Interest Expense | — | — | — | — | — | — | — |
| Pretax Income | $-314.7M | $-198.5M | $-117.7M | $-53.9M | $-38.8M | $-22.9M | $-16.5M |
| Income Tax Expense | $0 | $0 | $0 | $-426.0K | $579.0K | $-2.8M | $7.2M |
| Net Income | $-314.7M | $-198.5M | $-117.7M | $-53.5M | $-39.4M | $-20.1M | $-23.7M |
| Net Margin | -757.6% | -276.9% | -132.0% | -58.2% | -72.8% | -64.5% | -108.6% |
| EPS (Basic) | $-6.75 | $-5.07 | $-3.15 | $-1.59 | $-2.83 | $-8.02 | $-8.90 |
| EPS (Diluted) | $-6.75 | $-5.07 | $-3.15 | $-1.59 | $-2.83 | $-8.02 | $-8.90 |
| Shares Outstanding (Basic) | 48.8M | 42.2M | 37.7M | 37.1M | 31.2M | 3.6M | — |
| Shares Outstanding (Diluted) | 48.8M | 42.2M | 37.7M | 37.1M | 31.2M | 3.6M | — |
| Dividends Per Share | — | — | — | — | — | — | — |